2.9 million out of 200 million Nigerians absolutely vaccinated in opposition to COVID-19: NPHCDA

The Nationwide Major Well being Care Growth Company (NPHCDA) has disclosed that 2,897,201 eligible individuals had taken the jab throughout the 36 states and the Federal Capital Territory.

NPHCDA government director Faisal Shuaib introduced this on Tuesday, in Abuja, on the Nationwide Vaccines briefing.

Solely 2,897,201 million out of 200 million folks in Nigeria have obtained their full dose of the COVID-19 vaccine as of August 30, 2021, a far cry from the federal authorities’s objective of inoculating 70 per cent of its residents by the top of 2022.

In keeping with Mr Shuaib, the nation, which now has three COVID-19 vaccines accredited for emergency use by the World Well being Organisation (WHO), commenced its part two vaccination in 35 states and the FCT.

“For shoppers who haven’t had any vaccination, the Moderna vaccine is obtainable and is being administered in all designated well being services within the nation, whereas those that have had their first dose of AstraZeneca vaccine are inspired to go to their designated well being facility to get their second dose,” he mentioned.

The NPHCDA boss disclosed that the UK authorities had donated an extra 592,880 doses of the AstraZeneca-Oxford COVID-19 vaccine. It was obtained on August 26, 2021, via the COVAX Facility.

“I, due to this fact, use this chance to name on as soon as once more those that obtained the primary dose of AstraZeneca vaccine earlier than July 8, 2021, to go and get their second dose, to be absolutely protected in opposition to all strains of the coronavirus,” he added.

He known as on governors to proceed to supply management in mobilising residents to prioritise the acceptance of the COVID-19 vaccine.

“We’re significantly enthused by the instance of the Governor of Edo, Godwin Obaseki, as he mobilised church buildings and spiritual leaders in direction of mass acceptance of the COVID-19 vaccine,” mentioned the NPHCDA boss.


Learn extra

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button